



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/614,954	07/07/2003	Thomas M. Hohn	30884D	7143
7590 08/13/2004			EXAMINER	
Larry W. Stults, Ph.D. Syngenta Biotechnology, Inc.			IBRAHIM, MEDINA AHMED	
3054 Cornwalli		ART UNIT	PAPER NUMBER	
Research Triang	gle Park, NC 27709	1638		
			DATE MAIL ED: 08/13/200/	4

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applica	ition No.	Applicant(s)			
		10/614	,954	HOHN ET AL.			
Office Action Summary		Examin	er	Art Unit			
		Medina	A Ibrahim	1638			
Period fo	The MAILING DATE of this commun	ication appears on t	he cover sheet with the	correspondence address			
A SH THE - Exte after - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD F MAILING DATE OF THIS COMMUN nsions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this come a period for reply specified above is less than thirty (3) period for reply is specified above, the maximum st tre to reply within the set or extended period for reply reply received by the Office later than three months ed patent term adjustment. See 37 CFR 1.704(b).	ICATION. s of 37 CFR 1.136(a). In no nunication. sto) days, a reply within the statutory period will apply and will, by statute, cause the a	event, however, may a reply be tatutory minimum of thirty (30) did will expire SIX (6) MONTHS fro pplication to become ABANDON	timely filed  ays will be considered timely.  m the mailing date of this communication.  IED (35 U.S.C. § 133).			
Status							
1)⊠	Responsive to communication(s) file	ed on <u>23 <i>July 2004</i></u> .					
2a) <u></u>		2b)⊠ This action is	non-final.				
3)[	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims						
5)⊠ 6)⊠ 7)□	Claim(s) <u>1-6</u> is/are pending in the ap 4a) Of the above claim(s) <u>6</u> is/are wir Claim(s) <u>1-4</u> is/are allowed. Claim(s) <u>5</u> is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restrict	thdrawn from consid					
Applicati	on Papers						
10)⊠	The specification is objected to by the The drawing(s) filed on <u>07 July 2003</u> Applicant may not request that any objected to Replacement drawing sheet(s) including The oath or declaration is objected to	is/are: a) accept ction to the drawing(s) the correction is requ	be held in abeyance. So be held in abeyance. So bired if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).			
Priority u	ınder 35 U.S.C. § 119						
a)[	Acknowledgment is made of a claim  All b) Some * c) None of:  1. Certified copies of the priority  2. Certified copies of the priority  3. Copies of the certified copies application from the Internation see the attached detailed Office action	documents have be documents have be of the priority docun nal Bureau (PCT Ri	een received. een received in Applica nents have been receiv ule 17.2(a)).	tion No red in this National Stage			
Attachment			F				
2) 🔲 Notica 3) 🔯 Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (P nation Disclosure Statement(s) (PTO-1449 or 'No(s)/Mail Date		4) Interview Summar Paper No(s)/Mail D 5) Notice of Informal 6) Other:				

Application/Control Number: 10/614,954

Art Unit: 1638

## **DETAILED ACTION**

## Election/Restrictions

Applicant's election without traverse of Group I in the reply filed on 07/23/04 is acknowledged.

Claims 1-6 are pending.

Claims 1-5 are under consideration.

Claim 6 has been withdrawn from consideration as being directed to a nonelected invention.

# **Drawings**

The Examiner approves the drawings filed on 07/07/03.

## Information Disclosure Statement

The information disclosure statement (IDS) submitted on 07 July 2003 has been considered. However, references AS, AU and BA listed on page 2 of the IDS form 1449 will not be published on the face of the patent because they cite a hyperlink directed to an Internet address. The use of hyperlinks in the IDS is not allowed under USPTO current policy because the Internet address is subject to a change. Therefore, references AS, AU and BA are inappropriate references for publication on the face of the patent.

# Specification

The disclosure is objected to because of the following informalities: for example page 5, lines 22-23, and page 8, line 13, cite a hyperlink directed to an Internet address. The use of hyperlinks is not permitted under USPTO current policy because the content

= -

Application/Control Number: 10/614,954

Art Unit: 1638

= ~

of such links are subject to a change, resulting in the introduction of New Matter into the specification. Appropriate correction is required.

# **Priority**

The status of the U.S. Appl. No 10/074,279 on page 1, 1<sup>st</sup> paragraph, of the specification should be updated, i.e.---now US PAT 6,646,184--- should be inserted after "2002," in line 4.

# **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-5 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-2, 17-28, 186-200, and 231-245 of U. S. Patent No. 6,346,655. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims in both the application and the patent are directed to a transgenic host cell comprising SEQ ID NO: 5 or a nucleotide sequence encoding SEQ ID NO: 6. The transgenic host cell comprising a

Art Unit: 1638

~ <del>~</del> ~

chimeric gene comprising a nucleotide sequence encoding SEQ ID NO: 6 operably linked to a heterologous promoter is generic to a transgenic plant cell comprising a nucleotide sequence encoding SEQ ID NO: 6, and a transgenic plant cell comprising SEQ ID NO: 5 or nucleotide sequence having less than 100% sequence identity thereto. While the claims in the patent do not recite a"chimeric gene", a chimeric gene comprising a specific DNA is an obvious form of the specific DNA itself, since chimeric gene or recombinant DNA is the basis of the entire biotechnology industry. Also, a claim drawn to a transgenic plant cell comprising SEQ ID NO: 5 is generic to a claim drawn to SEQ ID NO:5. Since the claims in both this application and the application from the application (09/538,414) which gave rise to the '655 patent) were not subject to a restriction requirement, the obviousness double patenting rejection is proper.

#### Remarks

No claim has been allowed.

#### Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Medina A. Ibrahim whose telephone number is (571) 272-0797. The Examiner can normally be reached Monday -Thursday from 8:00AM to 5:30PM and every other Friday from 9:00AM to 5:00 PM . Before and after final responses should be directed to fax nos. (703) 872-9306 and (703) 872-9307, respectively.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Dr. Amy Nelson, can be reached at (571) 272-0804.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you

Application/Control Number: 10/614,954

Art Unit: 1638

have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mai

8/9/04

MEDINA A. IBRAHIM PATENT EXAMINER

Medina A. Ibrah

Page 5